|Systematic (IUPAC) name|
|topical, subcutaneous injection|
|CAS Registry Number||
|Molecular mass||582.8073 g/mol (predicted)|
|(what is this?)|
The substance is also used as a sclerosant, an irritant injected to treat varicose veins, under the trade names Asclera, Aethoxysklerol and Varithena. Polidocanol causes fibrosis inside varicose veins, occluding the lumen of the vessel, and reducing the appearance of the varicosity.
The FDA has approved polidocanol injections for the treatment of small varicose (less than 1 mm in diameter) and reticular veins (1 to 3 mm in diameter). Polidocanol works by damaging the cell lining of blood vessels, causing them to close and eventually be replaced by other types of tissue.
- "E45 itch relief cream". netdoctor.co.uk. Retrieved 2007-07-12.
- Sclerotherapy, Laurence Z Rosenberg, MD, eMedicine.com
- "Varithena™ (polidocanol injectable foam) For Intravenous Use. Full Prescribing Information" (PDF). Biocompatibles, Inc. Retrieved 1 October 2015.
- Facts and Companies: Varicose Vein Treatment Approved
- "Asclera Full Prescribing Information in Drug Reference Encyclopedia". Retrieved 2010-04-11.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|
|This dermatologic drug article is a stub. You can help Wikipedia by expanding it.|